MANGALAM DRUGS AND ORGANICS LTD
Q4 FY 20 RESULTS REVIEW
Mangalam
Drugs & Organics Limited has a diversified product range and is amongst the
top manufacturers in India in all the products it manufactures: Anti –
Malarial, Analgesic / Anti-Inflammatory, Anti – Hypertensive and Anti –
retroviral.
Mangalam
Drugs & Organics Limited commenced its manufacturing of Active
Pharmaceutical Ingredients (APIs) and Intermediates at VAPI – Gujarat in 1977.
It has a multi-product manufacturing facility on two locations, and an in-house
Research & Development laboratory recognized by the Department of
Scientific & Industrial Research, Delhi Govt. of India (DSIR).
Over
the last three decades, Mangalam has acquired worldwide reputation as a single
stop destination for frontline Anti-malaria. We also have a diversified product
range having synergies in operations and economies of scale. Mangalam is
amongst the top companies in Asia in all the products it makes; and is also the
largest manufacturer of some of its products in the world.
We
are presently focused in the manufacturing of the following:
Active Pharma Ingredients (APIs)
Intermediates
Specialty Chemicals
Along
with the WHO-GENEVA GMP Certification and EDQM approval for its API
manufacturing plant, the company is also in an agreement with the prestigious
Clinton Health Access Initiatives (CHAI) under its Fight Malaria Program for
supply of anti-malaria APIs worldwide.
Management
Govardhan M Dhoot Chairman & Managing
Director
Brijmohan M Dhoot Executive Director
|
Mangalam Drugs & Organics (in Rs. Cr.)
|
Mar '20
|
Dec '19
|
Sep '19
|
Jun '19
|
Mar '19
|
YOY
|
QOQ
|
|
Net Sales
|
88.09
|
61.94
|
67.27
|
65.04
|
48.09
|
83.18
|
42.22
|
|
Consumption of Raw Materials
|
52.8
|
37.44
|
45.66
|
42.17
|
37.37
|
41.29
|
41.03
|
|
Increase/Decrease in Stocks
|
10.84
|
4.08
|
0.57
|
1.78
|
-1.82
|
-695.6
|
165.69
|
|
Employees Cost
|
7.06
|
6.35
|
6.59
|
6.05
|
6.48
|
8.95
|
11.18
|
|
depreciat
|
2.1
|
2.06
|
2.27
|
1.8
|
1.66
|
26.51
|
1.94
|
|
Other Expenses
|
10.24
|
9.1
|
8.33
|
9.59
|
5.79
|
76.86
|
12.53
|
|
Other Income
|
0.45
|
0.66
|
0.03
|
0.04
|
0.21
|
114.29
|
-31.82
|
|
Interest
|
2.46
|
2.54
|
2.75
|
2.65
|
2.53
|
-2.77
|
-3.15
|
|
P/L Before Tax
|
3.05
|
1.02
|
1.14
|
1.04
|
-3.71
|
-182.21
|
199.02
|
|
Tax
|
-2
|
-0.64
|
0.33
|
0.3
|
2.29
|
-187.34
|
212.5
|
|
Net Profit
|
5.05
|
1.65
|
0.81
|
0.74
|
-6.01
|
184.03
|
206.06
|
|
Equity Share Capital
|
15.83
|
15.83
|
15.83
|
15.83
|
15.83
|
0
|
0
|
|
Basic EPS.
|
3.19
|
1.04
|
0.51
|
0.47
|
-3.8
|
-183.95
|
206.73
|
|
Diluted EPS.
|
3.19
|
1.04
|
0.51
|
0.47
|
-3.8
|
-183.95
|
206.73
|
MP 65.5
PE 5.13322884
52 Wk L/H 20.4 101.5
HIGH ON MAY 12TH 101.5
MAY 29TH 59.6
Valuation
Market Cap (Rs Cr.)
105.42
P/E
12.68
Book Value (Rs)
65.67
Industry P/E
31.19
EPS (TTM)
5.21
P/C
6.34
Price/Book
1.01
Face Value (RS)
10
Deliverables (%)
100
Share Holding Pattern in
(%)
Standalone Mar-20 Dec-19 Sep-19 Dec-18
Promoters 50.53 50.53 50.53 50.53
Pledged 61.89 0 0 24.94
FII/FPI 0 0 0 0
Total DII 5.97 5.9 6.03 7.57
Fin.Insts 0.01 0.08 0.03 0.06
Insurance Co 0 0 0 0
MF 0 0 0 0
Others DIIs 5.96 5.82 6 7.51
Others 43.5 43.58 43.44 41.9
Total 100 100.01 100 100
No comments:
Post a Comment